Exploiting the hydrophobic channel of the NNIBP: Discovery of novel diarylpyrimidines as HIV-1 NNRTIs against wild-type and K103N mutant viruses

被引:5
|
作者
Fu, Zhipeng [1 ]
Zhang, Tao [1 ]
Zhou, Zhongxia [1 ]
Kang, Dongwei [1 ]
Sun, Lin [1 ]
Gao, Shenghua [1 ]
Cherukupalli, Srinivasulu [1 ]
De Clercq, Erik [2 ]
Pannecouque, Christophe [2 ]
Liu, Xinyong [1 ,3 ]
Zhan, Peng [1 ,3 ]
机构
[1] Shandong Univ, Cheeloo Coll Med, Sch Pharmaceut Sci, Dept Med Chem,Key Lab Chem Biol,Minist Educ, 44 West Culture Rd, Jinan 250012, Shandong, Peoples R China
[2] Katholieke Univ Leuven, Rega Inst Med Res, Lab Virol & Chemotherapy, Herestr 49 Postbus 1043 09-A097, B-3000 Leuven, Belgium
[3] China Belgium Collaborat Res Ctr Innovat Antivira, 44 West Culture Rd, Jinan 250012, Shandong, Peoples R China
基金
中国国家自然科学基金;
关键词
HIV-1; NNRTI; Drug design; Drug resistance; Antiviral drug; REVERSE-TRANSCRIPTASE INHIBITORS; COLORIMETRIC ASSAY; ETRAVIRINE TMC125; DRUG; DERIVATIVES; POTENCY; DESIGN;
D O I
10.1016/j.bmc.2021.116239
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
To further explore the chemical space surrounding the "hydrophobic channel" of the NNRTI binding pocket (NNIBP), a new series of diarylpyrimidines (DAPYs) were designed and synthesized as potent HIV-1 nonnucleoside RT inhibitors (NNRTIs). The target compounds were evaluated for anti-HIV potency in MT-4 cells. Most of the synthesized DAPYs exhibited moderate to excellent activity against the HIV-1 wild-type (WT) strain with EC50 values ranging from 16 nM to 0.722 mu M. Interestingly, few compounds displayed remarkable activity in inhibiting K103N mutant virus with EC50 values ranging from 39 nM to 1.708 mu M. Notably, FS2 (EC50(IIIB) = 16 nM, EC50(K103N) = 39 nM, SI = 294) was identified as the most significant compound, which was considerably more potent than nevirapine, lamivudine, and comparable to zidovudine. Additionally, the HIV-1 RT inhibition assay confirmed their binding target. Preliminary structure-activity relationships (SARs) and molecular modeling studies were also performed, providing significant suggestions for further optimization.
引用
收藏
页数:11
相关论文
共 36 条
  • [31] Discovery of Wild-Type and Y181C Mutant Non-nucleoside HIV-1 Reverse Transcriptase Inhibitors Using Virtual Screening with Multiple Protein Structures
    Nichols, Sara E.
    Domaoal, Robert A.
    Thakur, Vinay V.
    Tirado-Rives, Julian
    Anderson, Karen S.
    Jorgensen, William L.
    JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2009, 49 (05) : 1272 - 1279
  • [32] Novel PCU cage diol peptides as potential targets against wild-type CSA HIV-1 protease: synthesis, biological screening and molecular modelling studies
    Karpoormath, Rajshekhar
    Sayed, Yasien
    Govender, Thavendran
    Kruger, Hendrik G.
    Soliman, Mahmoud E. S.
    Maguire, Glenn E. M.
    MEDICINAL CHEMISTRY RESEARCH, 2013, 22 (08) : 3918 - 3933
  • [33] Discovery of piperidin-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-Benzyl derivatives with broad potency against resistant mutant viruses
    Kertesz, Denis J.
    Brotherton-Pleiss, Christine
    Yang, Minmin
    Wang, Zhanguo
    Lin, Xianfeng
    Qiu, Zongxing
    Hirschfeld, Donald R.
    Gleason, Shelley
    Mirzadegan, Taraneh
    Dunten, Pete W.
    Harris, Seth F.
    Villasenor, Armando G.
    Hang, Julie Qi
    Heilek, Gabrielle M.
    Klumpp, Klaus
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (14) : 4215 - 4218
  • [34] Halogen Bond Interactions of Novel HIV-1 Protease Inhibitors (PI) (GRL-001-15 and GRL-003-15) with the Flap of Protease Are Critical for Their Potent Activity against Wild-Type HIV-1 and Multi-PI-Resistant Variants
    Hattori, Shin-ichiro
    Hayashi, Hironori
    Bulut, Haydar
    Rao, Kalapala Venkateswara
    Nyalapatla, Prasanth R.
    Hasegawa, Kazuya
    Aoki, Manabu
    Ghosh, Arun K.
    Mitsuya, Hiroaki
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2019, 63 (06)
  • [35] DB-02, a C-6-Cyclohexylmethyl Substituted Pyrimidinone HIV-1 Reverse Transcriptase Inhibitor with Nanomolar Activity, Displays an Improved Sensitivity against K103N or Y181C Than S-DABOs
    Zhang, Xing-Jie
    Lu, Li-He
    Wang, Rui-Rui
    Wang, Yue-Ping
    Luo, Rong-Hua
    Lai, Christopher Cong
    Yang, Liu-Meng
    He, Yan-Ping
    Zheng, Yong-Tang
    PLOS ONE, 2013, 8 (11):
  • [36] Insights into the interaction mechanism of first-generation HIV-1 protease inhibitors with wild-type and mutant (D30N and L76V) enzymes through in-silico based approach
    Pandarinathan, S.
    Jayanthi, S.
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2025,